Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin
-
By
May 23, 2023
-
20 min
-
1
Multiple myeloma is characterized by plasma cell abnormalities.
-
2
Belantamab mafodotin is a promising therapy for refractory myeloma but is associated with corneal toxicity.
-
3
Patient education and dose modifications are crucial in managing ocular toxicities.
-
4
Belantamab mafodotin received accelerated approval but faced setbacks in a phase III trial.
-
5
Clinical studies (DREAMM-7, DREAMM-8, and DREAMM-9) continue to investigate belantamab mafodotin's efficacy.
-
Multiple myeloma, a malignancy characterized by plasma cell abnormalities, has seen improvements in treatment over the past 20 years. Belantamab mafodotin (Blenrep) is a promising therapy for refractory myeloma but is associated with ocular toxicity. This article discusses its mechanism of action, safety, and efficacy data, emphasizing its impact on the cornea. Patient education, dose modifications, and the Risk Evaluation and Mitigation Strategy are essential elements in managing ocular toxicities. Despite accelerated approval, belantamab mafodotin has experienced setbacks in a phase III trial, prompting continued investigation through clinical studies (DREAMM-7, DREAMM-8, and DREAMM-9).
-
1
Multiple myeloma is characterized by plasma cell abnormalities.
-
2
Belantamab mafodotin is a promising therapy for refractory myeloma but is associated with corneal toxicity.
-
3
Patient education and dose modifications are crucial in managing ocular toxicities.
-
4
Belantamab mafodotin received accelerated approval but faced setbacks in a phase III trial.
-
5
Clinical studies (DREAMM-7, DREAMM-8, and DREAMM-9) continue to investigate belantamab mafodotin's efficacy.
Listen Tab content